Research programme: antibacterials - Amoebics

Drug Profile

Research programme: antibacterials - Amoebics

Alternative Names: antibody-protein therapeutics -Amoebics; VenFc

Latest Information Update: 16 Apr 2007

Price : $50

At a glance

  • Originator Amoebics
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Staphylococcal infections

Most Recent Events

  • 16 Apr 2007 This programme is still in active development
  • 25 Jan 2006 Preclinical trials in Staphylococcal infections in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top